

University of Groningen

Pathophysiology and management of hemostatic alterations in cirrhosis and liver transplantation

Arshad, Freeha

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:
2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Arshad, F. (2016). *Pathophysiology and management of hemostatic alterations in cirrhosis and liver transplantation*. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

**Pathophysiology and Management
of Hemostatic Alterations in Cirrhosis
and Liver Transplantation**

Freeha Arshad

The study described in Chapter 7 was partially funded by Sanquin Plasma Products B.V.
For printing of this thesis, financial support of the following institutions and companies
is gratefully acknowledged:

Arshad, F
**Pathophysiology and management of hemostatic alterations in cirrhosis and liver
transplantation**

Thesis, University of Groningen, the Netherlands

E-publication available at <https://epubs.ogc.nl/?epub=f.arshad>

ISBN (printed version): 978-94-6169-908-4

ISBN (electronic version): 978-94-6169-924-4

© Copyright 2016 Freeha Arshad, the Netherlands

All rights reserved. No parts of this thesis may be reproduced, stored in a retrieval
system or transmitted in any form or by any means, without permission of the author.

Cover design: Freeha Arshad

Lay-out and printed by: Optima Grafische Communicatie, Rotterdam, the Netherlands



rijksuniversiteit
 groningen

**Pathophysiology and Management of
 Hemostatic Alterations in Cirrhosis
 and Liver Transplantation**

Proefschrift

ter verkrijging van de graad van doctor aan de
 Rijksuniversiteit Groningen
 op gezag van de
 rector magnificus prof. dr. E. Sterken
 en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 7 september 2016 om 14.30 uur

door

Freeha Arshad
 geboren op 22 april 1984
 te Amsterdam

Promotores

Prof. dr. R. J. Porte

Prof. dr. T. Lisman

Copromotor

Dr. M.T. de Boer

Beoordelingscommissie

Prof. dr. A.M.G.A. de Smet

Prof. dr. J. Pirenne

Prof. dr. K. Meijer

TABLE OF CONTENTS

Chapter 1	General introduction and outline of this thesis	9
Part A. Hemostatic drugs in patients with cirrhosis		
Chapter 2	Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis <i>Liver International. 2015;35:1809-1815.</i>	21
Chapter 3	Differential <i>in vitro</i> inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis <i>PlosOne. 2014;9:e88390; doi:10.1371/journal.pone.0088390.</i>	35
Chapter 4	Routine coagulation assays underestimate levels of antithrombin-dependent but not of direct anticoagulant drugs in plasma from patients with cirrhosis <i>British Journal of Haematology. 2013;163:666-673.</i>	55
Part B. Blood loss and prevention of blood loss and RBC transfusion during liver transplantation		
Chapter 5	Physiology, prevention, and treatment of blood loss during liver transplantation <i>In: Wagener G, editor. Liver Anesthesiology and Critical Care Medicine. Springer; 2012. p. 169-179.</i>	73
Chapter 6	Red blood cell transfusion requirements during orthotopic liver transplantation have increased after market withdrawal of aprotinin <i>Submitted for publication.</i>	93
Chapter 7	Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial <i>BMC Surgery. 2013; 13: 22.</i>	107

Chapter 8	Serum markers of portal hypertension are associated with blood loss and transfusion requirements during orthotopic liver transplantation <i>Submitted for publication.</i>	131
------------------	---	-----

Part C. The hemostatic status of the liver transplant recipient

Chapter 9	Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient <i>Liver International. 2013;33:820-827.</i>	145
------------------	---	-----

Chapter 10	Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation <i>F1000. 2014;3:103. doi:10.12688/f1000research.3980.2.</i>	163
-------------------	---	-----

Chapter 11	Summary	181
-------------------	---------	-----

Chapter 12	Discussion and future perspectives	189
	Nederlandse samenvatting	205
	List of publications	213
	Dankwoord	219
	Biography	201
	List of abbreviations	229

